ANSWER ALS’ Post

Unlocking the Future of Medicine! 🌟 Dive into the groundbreaking world of targeted spatial profiling in multi-omics, where revolutionary therapeutic advances await. 🚀 Discover how this cutting-edge technology is reshaping healthcare as we know it: https://lnkd.in/esYzpV6P #MedicalInnovation #MultiOmics #TherapeuticAdvances #TargetedBioscience

Launching SYNTHIA, a pioneering public-private partnership funded by the Innovative Health Initiative (IHI). The SYNTHIA project, a groundbreaking public-private partnership set to revolutionize the field of personalized medicine by harnessing the power of synthetic data. As the first IHI project to tackle the critical need for privacy-preserving data solutions in healthcare, SYNTHIA aims to propel research and innovation to new heights, ensuring that patients receive the best possible care while safeguarding their personal information. SYNTHIA is a multidisciplinary collaboration of 32 consortium partners - SDG developers, FAIR data experts, clinical researchers, developers of therapies and data-based tools, legal experts, socio-economic analysts, regulatory, policy advocacy, and communication experts - that will provide a 360º vision on how to advance healthcare applications through SD use Synthetic data, which are artificially generated to mimic real patient data, present a solution to many of the challenges faced in health research today. These data allow researchers to overcome the limitations of access to high-quality, real-world datasets and address growing concerns about patient privacy. However, questions have lingered about the quality and applicability of synthetic datasets, especially in diverse and complex scenarios. SYNTHIA is addressing these challenges head-on by developing validated tools and methods for synthetic data generation (SDG) across various data types, including laboratory results, clinical notes, genomics and imaging. By focusing on six specific diseases the project will demonstrate the utility of synthetic data in advancing personalized medicine: Lung cancer, Breast cancer, Multiple myeloma, Diffuse large B-cell lymphoma, Alzheimer’s disease and Type 2 diabetes. Stay tuned for our press release! This project is supported by the Innovative Health Initiative (IHI) Joint Undertaking (IHI JU) under grant agreement No 101172872. The JU receives support from the European Commission European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA - European Federation of Pharmaceutical Industries and Associations, EuropaBio - the European Association for Bioindustries, MedTechEurope, and VaccinesEurope and DNV. #SYNTHIA_SyntheticData #DataGeneration #FutureOfMedicine #Datascience #EUInnovation #HealthResearch

🚀 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐒𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 🧬 📌𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅𝐬 𝐚𝐭 𝐘𝐨𝐮𝐫 𝐅𝐢𝐧𝐠𝐞𝐫𝐭𝐢𝐩𝐬: https://lnkd.in/dKwRNaaa (𝙐𝙨𝙚 𝘾𝙤𝙧𝙥𝙤𝙧𝙖𝙩𝙚 𝙈𝙖𝙞𝙡 𝙄𝙙 𝙛𝙤𝙧 𝙌𝙪𝙞𝙘𝙠 𝙍𝙚𝙨𝙥𝙤𝙣𝙨𝙚) In the rapidly evolving world of healthcare, Clinical Next-Generation Sequencing (NGS) is revolutionizing how we understand and treat diseases. By enabling high-throughput analysis of genetic variations, NGS provides unprecedented insights into complex conditions like cancer, genetic disorders, and infectious diseases. 🔍 With Clinical NGS, we're moving beyond traditional diagnostic methods to a more personalized approach to medicine. It allows for: ✔ 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬: Identifying mutations and genetic markers with high accuracy. ✔ 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: Tailoring treatments based on an individual’s genetic profile. ✔ 𝐄𝐚𝐫𝐥𝐲 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧: Spotting potential health issues before they become critical. 📌𝑲𝒆𝒚 𝑪𝒐𝒎𝒑𝒂𝒏𝒊𝒆𝒔 𝑷𝒓𝒐𝒇𝒊𝒍𝒆𝒅: Agilent Technologies, Illumina, Thermo Fisher Scientific, Eurofins Scientific AG (Switzerland), BGI Group, QIAGEN, Roche Diagnostics UK & Ireland, DNASTAR, Bio-Rad Laboratories, Congenica, theragen etex co, PerkinElmer, Partek, an Illumina company, Oxford Nanopore Technologies, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. WHICH WILL DO BUSINESS IN CALIFORNIA AS PAC BIO, INC., Golden Helix, Inc., Pierian As we continue to advance this technology, the possibilities for improving patient outcomes and transforming healthcare are endless. Let's embrace the power of Clinical NGS and drive the future of precision medicine together! 🌟 📌Source: Creative Biolabs 📌Disclaimer- I don't intend any copyright (DM me for credit & removal) #ClinicalNGS #NextGenSequencing #PrecisionMedicine #Genomics #NGSTechnology #MolecularDiagnostics #GeneticTesting #PersonalizedMedicine #ClinicalGenomics #SequencingInnovation #GenomicResearch #HealthTech #GeneticAnalysis #Bioinformatics #NGSApplications #GenomicMedicine #DNASequencing #HealthcareInnovation #FutureOfMedicine #ClinicalResearch

#cellandgenetherapy requires a new development paradigm. When we started T2EVOLVE Consortium the plan was to engage with regulators as early as possible. I thought the focus would be on qualifying a preclinical model. Thanks to the tireless efforts of Carmen Sanges, PhD the consortium has leveraged its collective intelligence to focus on a topic with much greater #innovation #impact. One of the biggest potential advantages of #ATMPs is that ability to rapidly iterate and engineer new therapies. Being able to speed up the regulatory process to allow iterations to move forward more rapidly would be a great way to accelerate CAR-T development. Read the nice article by the Innovative Health Initiative (IHI) to learn more. Hélène NEGRE Magda Chlebus Niklas Blomberg Hugh Laverty Rashmi Choudhary Michael Hudecek

We have a busy March coming up! Come to our stand to learn about our consistent, defined, and scalable hiPSC-derived ioCells™ powered by opti-ox™, including ioDisease Model Cells™, genetically matched ioWild Type Cells™, and ioCRISPR-Ready Cells™. Find out how this toolbox can help you study the impact of mutations related to Alzheimer’s and Parkinson’s disease in human CNS cells, identify novel therapeutic targets and enhance the translational relevance of your disease research and drug discovery. Next week, you can find our team at #ADPD24 booth #56. Explore the ioCells toolbox: https://hubs.ly/Q02mQns20 See all upcoming events: https://hubs.ly/Q02mQB2s0 #research #DrugDiscovery #AlzheimersDisease #ParkinsonsDisease #science #data #optiox #ioCells #ioDiseaseModelCells #microglia #HTS #ADPD #ADPD2024 #ARUK24 #ARUK

🌐 Addressing Unmet Medical Needs: A Call to Innovation In the dynamic landscape of healthcare, there exist numerous unmet medical needs—conditions lacking adequate treatments or cures. These gaps challenge us to push the boundaries of medical research and innovation. 🚀 Examples of Unmet Needs: Rare diseases with limited therapeutic options. Antibiotic resistance threatening global health. Neurological disorders awaiting breakthrough treatments. 💡 Innovation at the Helm: Efforts to address unmet needs involve groundbreaking technologies like precision medicine, gene therapies, and advanced biotech solutions. The collaboration between researchers, industry, and advocacy groups is paramount. 🌍 Global Impact: Unmet medical needs are not confined by borders. Global collaboration and shared efforts are essential to finding solutions that benefit diverse populations. 🤝 Patient Advocacy Matters: Patient advocacy groups play a vital role in raising awareness, driving research, and influencing policies to bridge the gaps in healthcare. 🔍 Current Challenges and Future Prospects: From rare diseases to infectious threats, each challenge presents an opportunity for transformative solutions. The future holds promise with advancements in AI, gene editing, and personalized medicine. 🌟 Join the Conversation: Let's discuss the unmet medical needs that matter most to you. What breakthroughs do you hope to see in healthcare innovation? Together, we can drive change and make a lasting impact on global health. #UnmetMedicalNeeds #HealthcareInnovation #MedicalResearch #GlobalHealth #usfda #ushealthcare #ResponsiveDelivery #PrecisionMedicine #TargetedTherapies #PolymerDrugConjugates #BiodegradablePolymers #SustainablePharma #PharmaInnovation  #DrugDelivery #Innovation #PolymerScience #genericdrugs #PharmaceuticalScience #FormulationExcellence #RegulatoryCompliance #PharmaceuticalSupplyChain #FutureOfPharma #formulationdevelopment #pharmaceuticalindustry #pharmaceuticalmanufacturing #pharmaceuticalinnovation #pharmanews #scienceinnovation #sciencenews #fdaregulations #mhra #fda #healthcanada #emea #healthcare #researchanddevelopment #businessdevelopment 

We have a busy April coming up! Come to our stand to learn about our consistent, defined, and scalable hiPSC-derived ioCells™ powered by opti-ox™, including ioDisease Model Cells™, genetically matched ioWild Type Cells™, and ioCRISPR-Ready Cells™. Find out how this toolbox can help you study the impact of mutations related to Alzheimer’s and Parkinson’s disease in human CNS cells, identify novel therapeutic targets and enhance the translational relevance of your disease research and drug discovery. Explore the ioCells toolbox: https://hubs.ly/Q02r1YnD0 See all upcoming events: https://hubs.ly/Q02r1YDD0 #research #DrugDiscovery #AlzheimersDisease #ParkinsonsDisease #science #data #optiox #ioCells #ioDiseaseModelCells #microglia #HTS

Helix Launches Clinico-Genomic Datasets to Accelerate Precision Medicine Drug Discovery - HIT Consultant #HelixLaunchesClinicoGenomicDatasets: Helix, a healthcare IT company, has recently launched new clinico-genomic datasets to speed up precision medicine drug discovery. This initiative aims to revolutionize the way healthcare professionals approach personalized medicine. #BenefitsOfClinicoGenomicDatasets: The blog post discusses the numerous benefits of utilizing clinico-genomic datasets in healthcare IT. These datasets can provide valuable insights into patient health, genetics, and treatment outcomes, ultimately leading to more effective personalized medicine strategies. #ImpactOnPrecisionMedicine: By leveraging clinico-genomic datasets, healthcare IT professionals can significantly impact precision medicine. These datasets allow for a deeper understanding of the relationship between genetics, health conditions, and treatment responses, leading to ai.mediformatica.com #data #clinical #this #dataset #datasets #health #clinicaldata #lifescience #drugdiscovery #genomicdata #genomics #healthsystems #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3Kx7cR5)

Today Lifebit has announced a major milestone of reaching over 100M patients’ data, covering health and multi-omic data from its global data partnerships. Lifebit’s data catalog includes comprehensive multi-omic and health datasets, representing over 200 health conditions from more than 30 data partners - the world’s most diverse genomic and health data resources - absolutely pivotal for pharma R&D and advancing precision medicine. Uniquely, these data cover disease areas posing the greatest threats to human health, including cancer, cardiovascular, respiratory, neurological, diabetes, and rare diseases. If you’re in pharma, take a look and see how Lifebit can support your data needs. Read our press release here: https://bit.ly/4c4q72f #PrecisionMedicine #Biotech #DataInnovation #Lifebit #datasaveslives